1alpha, 25-Dihydroxy VD2-D6 - CAS 216244-04-1
Not Intended for Therapeutic Use. For research use only.
Product Name:
1alpha, 25-Dihydroxy VD2-D6
Catalog Number:
1alpha, 25-Dihydroxy VD2-D6
CAS Number:
Molecular Weight:
Molecular Formula:
Chemical Structure
CAS 216244-04-1 1alpha, 25-Dihydroxy VD2-D6

Related VD/VDR Products

(CAS: 233268-78-5)

LG190155 is a moderately potent VDR agonist.

CAS 60133-18-8 Ercalcitriol

(CAS: 60133-18-8)

Ercalcitriol is a active metabolite of vitamin D2. It exhibits equipotent antirachitic activity in rats as calcitriol.

CAS 29261-12-9 25,26-Dihydroxyvitamin D3

25,26-Dihydroxyvitamin D3
(CAS: 29261-12-9)

Α hydroxylated metabolite of Vitamin D3

CAS 83805-11-2 Falecalcitriol

(CAS: 83805-11-2)

Falecalcitriol is an analog of calcitriol. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo.

CAS 67-97-0 Cholecalciferol

(CAS: 67-97-0)

Cholecalciferol is a naturally occuring form of vitamin D which is obtained from dietary sources, such as fish, or through the conversion of 7-dehydrocholestero...

CAS 112849-14-6 (24S)-MC 976

(24S)-MC 976
(CAS: 112849-14-6)

(24S)-MC 976 is a Vitamin D3 derivative.

CAS 21343-40-8 Ercalcidiol

(CAS: 21343-40-8)

A metabolite of Vitamin D2

CAS 1262843-46-8 25-Hydroxy VD2-D6

25-Hydroxy VD2-D6
(CAS: 1262843-46-8)

A labelled metabolite of Vitamin D2

CAS 118584-54-6 VD3-D6

(CAS: 118584-54-6)

VD3-D6(Vitamin D3-26,26,26,27,27,27-d6) is the deuterated form of Vitamin D3; tools for determination of Vitamin D3 metabolites in human serum.

CAS 54573-75-0 Doxercalciferol

(CAS: 54573-75-0)

Doxercalciferol (Hectorol; 1.alpha.-Hydroxyvitamin D2) is a synthetic analog of vitamin D; is a Vitamin D2 analog that acts as a vitamin D receptor activator (V...

CAS 134404-52-7 Seocalcitol

(CAS: 134404-52-7)

Seocalcitol is a vitamin D receptor (VDR) agonist. Seocalcitol exhibits anti-tumor and anti-proliferative activity with reduced hypercalcemic effects

CAS 112827-99-3 24R-Calcipotriol

(CAS: 112827-99-3)

24R-Calcipotriol is an impurity of Calcipotriol, which is a ligand of VDR-like receptors.

CAS 40013-87-4 24, 25-Dihydroxy VD3

24, 25-Dihydroxy VD3
(CAS: 40013-87-4)

24, 25-Dihydroxy VD3 is a compound which is closely related to 1,25-dihydroxyvitamin D3, the active form of vitamin D3, but like vitamin D3 itself and 25-hydrox...

CAS 113082-99-8 Calcipotriol Impurity C

Calcipotriol Impurity C
(CAS: 113082-99-8)

Calcipotriol Impurity C, the trans-isomeric impurity of Calcipotriene, is an analogue of VD3 which could be an agonist of vitamin D receptor.

CAS 32222-06-3 Calcitriol

(CAS: 32222-06-3)

Calcitriol is the hormonally active form of vitamin D.

CAS 457048-34-9 1α, 24, 25-Trihydroxy VD2

1α, 24, 25-Trihydroxy VD2
(CAS: 457048-34-9)

1alpha, 24, 25-Trihydroxy VD2 is a vitamin D analog.

CAS 129831-99-8 MC 976

MC 976
(CAS: 129831-99-8)

MC 969 is an analog of the calcemic drug 1α-hydroxyvitamin D3 (1α-OH-D3) in which carbons 25, 26, and 27 in the side chain are incorporated into a cyclopropane ...

CAS 126860-83-1 MC 1046

MC 1046
(CAS: 126860-83-1)

MC 1046 is a vitamin D3 analogue with similar effects. Impurity of Calcipotriol, an antipsoriatic.

CAS 163018-26-6 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3

3-O-(2-Aminoethyl)-25-hydroxyvitamin D3
(CAS: 163018-26-6)

Vitamin D3 analog.

Reference Reading

1.Synthesis, metabolism, and biological activity of 2-[3-(tetrazolyl)propyl]-1α,25-dihydroxy-19-norvitamin D3.
Takano M1, Yasuda K2, Higuchi E1, Tohyama E2, Takeuchi A3, Sakaki T2, Kittaka A4. J Steroid Biochem Mol Biol. 2015 Jul 29. pii: S0960-0760(15)30029-7. doi: 10.1016/j.jsbmb.2015.07.016. [Epub ahead of print]
Recently, we found that 2α-[2-(tetrazol-2-yl)ethyl]-1α,25-dihydroxyvitamin D3 showed higher osteocalcin promoter transactivation activity in human osteosarcoma (HOS) cells and a greater therapeutic effect in ovariectomized (OVX) rats in vivo than those of active vitamin D3, 1α,25(OH)2D3. We were interested in introducing a heterocyclic ring to the C2 position of the seco-steroidal structure via an alkyl linker, and four novel C2-(3-tetrazolylpropyl) substituted 1α,25-dihydroxy-19-norvitamin D3 analogs, 2α-[3-(tetrazol-1-yl)propyl]-, 2β-[3-(tetrazol-1-yl)propyl]-, 2α-[3-(tetrazol-2-yl)propyl]-, and 2β-[3-(tetrazol-2-yl)propyl]-19-nor-1α,25(OH)2D3 were synthesized. Among them, 2α-[3-(tetrazol-1-yl)propyl]-19-nor-1α,25(OH)2D3 showed weak binding affinity for human vitamin D receptor (hVDR) (2.6% of 1α,25(OH)2D3 and ca. 15% of 19-nor-1α,25(OH)2D3) and weak VDR transactivation activity in HOS cells (EC50 7.3nM, when 1α,25(OH)2D30.23nM). Although the other three compounds could not act as VDR binders by evaluation of the competition assays, 2α-[3-(tetrazol-2-yl)propyl]-19-nor-1α,25(OH)2D3 showed weak transactivation activity (EC50 12.
2.A new suprasterol by photochemical reaction of 1α,25-dihydroxy-9-methylene-19-norvitamin D3.
Kulesza U1, Plum LA2, DeLuca HF2, Mouriño A3, Sicinski RR4. Org Biomol Chem. 2016 Jan 27;14(5):1646-52. doi: 10.1039/c5ob01896j.
The UV-induced photochemical reaction of 1α,25-dihydroxy-9-methylene-19-norvitamin D3 has been investigated. The pentacyclic structure of the isolated product has been unequivocally established by X-ray crystallographic analysis. The possible reaction paths of the examined photochemical transformation are discussed. Biological in vivo and in vitro tests proved that the photoproduct is devoid of calcemic activity.
3.Long-term treatment with eldecalcitol (1α, 25-dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3) suppresses bone turnover and leads to prevention of bone loss and bone fragility in ovariectomized rats.
Takeda S1, Smith SY, Tamura T, Saito H, Takahashi F, Samadfam R, Haile S, Doyle N, Endo K. Calcif Tissue Int. 2015 Jan;96(1):45-55. doi: 10.1007/s00223-014-9937-5. Epub 2014 Dec 4.
The purpose of this study is to estimate the efficacy of eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3; ELD) on bone metabolism after long-term administration. Six-month-old Wistar-Imamichi rats were ovariectomized (OVX) and administered ELD orally at doses of 7.5, 15, or 30 ng/kg daily. Bone mineral density (BMD), urinary excretion of deoxypyridinoline (DPD), a bone resorption marker, and serum total alkaline phosphatase (ALP), a surrogate marker of bone formation, were assessed after 3, 6, and 12 months of treatment. After 12 months of treatment, the biomechanical strength of the L4 lumbar vertebra and femoral shaft was measured, and bone histomorphometry was performed on the L3 lumbar vertebra and the tibia diaphysis. ELD prevented OVX-induced decreases in BMD of the lumbar vertebrae and femur throughout the treatment period. ELD significantly suppressed OVX-induced increases in urinary DPD excretion throughout the treatment period with minimal effects on ALP.
4.Synthesis and properties of 14-epi-1α,25-dihydroxy-19-nortachysterol and its 2-substituted derivatives.
Sawada D, Kittaka A1. Curr Top Med Chem. 2014;14(21):2454-9.
As the first stable tachysterol analogs, 14-epi-19-nortachysterol and its 2-substituted derivatives were synthesized using the Stille coupling reaction between the A-ring precursor (three vinylstannanes) and the CD-ring vinyl trifrate. Among them, the 2-methylidene group was hydrogenated with Wilkinson's catalyst regioselectively to obtain 2α- and 2β-methyl analogs after separation; therefore, five new 14-epi-19- nortachysterols were constructed. All 14-epi-19-nortachysterols showed moderate to strong human vitamin D receptor (hVDR) binding affinity except the 2α-(3-hydroxypropoxy) substituted analog. X-ray cocrystallographic analysis of the [truncated hVDR]-[2-methyl-14-epi-19-nortachysterol] complex exhibited an unusual binding structure that has not been observed previously.